{"database":"ecrin-mdr-crc","file_versions":[],"scores":null,"additional":{"omics_type":["Clinical"],"study_start_year":["2022"],"data_sharing_plan":["IPD Sharing (as of March 2023): No"],"condition":["Colorectal Carcinoma","Colorectal Neoplasms"],"disease":["Colorectal Carcinoma","Colorectal Neoplasms"],"study_type":["Interventional"],"full_dataset_link":["https://newmdr.ecrin.org/Study/13857"],"location":["China"],"study_start_month":["9"],"keyword":["Oxaliplatin","Capecitabine","Bevacizumab"],"repository":["ECRIN MDR"],"study_status":["Recruiting"],"additional_accession":[]},"is_claimable":false,"name":"QL1706 Monotherapy or in Combination With Bevacizumab and XELOX as First-line Treatment of Unresectable Advanced or Metastatic CRC","description":"This is an open-label, muticenter phase II study to evaluate the efficacy and safety of QL1706 monotherapy or in combination with bevacizumab and XELOX as first-line treatment of unresectable advanced or metastatic CRC.","dates":{"creation":"2022-09-15"},"accession":"13857","cross_references":{"ClinicalTrials___gov":["NCT05799820"]}}